塞夫托比普罗尔用于治疗复杂的金黄色葡萄球菌菌病
Thomas L Holland1, Sara E Cosgrove1, Sarah B Doernberg1
1From the Division of Infectious Diseases, Duke University (T.L.H., N.A.T., V.G.F.), and Duke Clinical Research Institute (T.L.H., V.G.F.) - both in Durham, NC; the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (S.E.C.); the Division of Infectious Diseases, Department of Medicine, University of California, San Francisco, San Francisco (S.B.D.); the Division of Infectious Diseases, Department of Medicine, Denver Health, Denver (T.C.J.); Tufts Medicine and Tufts University School of Medicine, Boston (H.W.B.); Zaycev V.T. Institute of General and Emergency Surgery of the National Academy of Medical Sciences of Ukraine, Kharkiv (O.P.), Regional Clinical Hospital, Ivano-Frankivsk Regional Council, Ivano-Frankivsk (I.T.), and Dnipropetrovsk I.I. Mechnikov Regional Clinical Hospital, Dnipro (S.K.) - all in Ukraine; Eurohospital Plovdiv, Plovdiv (B.A.), and University Multiprofile Hospital for Active Treatment and Emergency Medicine "N.I. Pirogov," Clinic of Purulent-Septic Surgery, Sofia (I.P.) - both in Bulgaria; LTD Academician Vakhtang Bochorishvili Clinic, Tbilisi, Georgia (M.M.); N.I. Pirogov City Clinical Hospital No. 1, Moscow (A.A.); the Department of Medicine and Division of Infectious Diseases, Centro de Educación Médica e Investigaciones Clínicas, Buenos Aires (M.E.S.); Basilea Pharmaceutica International, Allschwil, Switzerland (M.A.G., M.E., K.H., D.I., M.J., M.S., J.S.); and the Institute for Medical Microbiology, Immunology, and Hygiene, Medical Faculty and University Hospital Cologne, University of Cologne, and the German Center for Infection Research, Partner Site Bonn-Cologne - both in Cologne, Germany (H.S.).
塞夫托比普罗尔在治疗复杂的黄金杆菌菌菌症治疗中表现出与达普托米辛的非劣势. 这一发现支持 ceftobiprole作为这些严重感染的有效治疗选择.
科学领域:
- 传染性疾病 传染性疾病
- 临床药理学 临床药理学
- 抗微生物耐药性 抗微生物耐药性
背景情况:
- 复杂的金黄色葡萄球菌菌病,包括耐甲素菌株,构成了重大的治疗挑战.
- 塞法洛斯波林抗生素Ceftobiprole已经显示出对S. aureus的潜在有效性.
- 评估新的治疗策略对于管理具有挑战性的细菌感染至关重要.
研究的目的:
- 为了确定 ceftobiprole 是否在治疗复杂的 Staphylococcus aureus bacteremia 中与达普托米辛无差.
- 为了比较 ceftobiprole 和 daptomycin 之间的整体治疗成功率.
- 评估两种抗生素方案的安全性.
主要方法:
- 第三阶段,双盲,双假人,非劣等性试验设计.
- 随机 1: 1 分配给 ceftobiprole 或 daptomycin (可选使用 aztreonam).
- 主要结果:在70天的整体治疗成功,由盲目委员会裁决.
主要成果:
- 整体治疗成功率在 ceftobiprole组达到69.8%,在 daptomycin组达到68.7%.
- 死亡率在各组之间是相似的 (9.0%对9.1%).
- 胃肠道不良事件更频繁地发生在 ceftobiprole.
结论:
- 塞夫托比普罗尔对复杂的黄金杆菌菌菌病的治疗效果不逊于达普托米辛.
- 塞夫托比普罗尔为这些感染提供了可行的替代治疗方法.
- 进一步的研究可能会探索长期结果和特定患者群体.
更多相关视频
09:26Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
07:16Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis
Published on: September 20, 2024
相关概念视频
Urinary Tract Infection IV: Nursing Management
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Acute Pyelonephritis II: Diagnostic Studies and Management
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Endocarditis IV: Nursing Management
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
